/
EVAX
$3.20+$0.11 (+3.56%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$25.8M
8M shares
52-week range
$2.26 – $12.15
10% from low
Exchange
NASDAQ
ADRC
Borrow rate
2.28%
Moderate
Price (6 mo)
Loading chart…
Change$-368.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $73.0K | $3.3M | $7.5M |
| Cost of revenue | $73.9K | $81.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$73.9K | −$81.0K | $0 | $0 | $0 | $73.0K | $3.3M | $7.5M |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| R&D | $3.7M | $8.6M | $11.7M | $19.6M | $17.1M | $11.9M | $10.5M | $10.0M |
| Operating income | −$5.6M | −$11.4M | −$16.6M | −$25.8M | −$25.3M | −$22.2M | −$14.7M | −$9.2M |
| EBITDA | −$6.2M | −$11.9M | −$16.5M | −$24.2M | −$22.6M | −$21.4M | −$9.8M | −$7.1M |
| Net income | −$5.5M | −$11.2M | −$15.0M | −$24.5M | −$23.2M | −$22.1M | −$10.6M | −$7.7M |
| Net margin | — | — | — | — | — | -30308.2% | -316.0% | -102.4% |
| EPS (diluted) | -11.52 | -27.60 | -37.00 | -50.40 | -39.20 | -32.40 | -9.80 | -1.21 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2027 | $23M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $24M | $-0.03 | $-0.24–$0.18 | 2 |
| 2029 | $73M | $0.08 | $0.08–$0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$37.55
Price
$3.20
Implied upside
+1073%
Peer comparison
Evaxion A/S American Depositary Share
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
www.evaxion.ai- Employees
- 46
- IPO / List date
- Feb 5, 2021
Held by traders on TradeandTell
No one on the platform currently holds EVAX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 39,225 | $145.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-14 | 1-for-5reverse |
| 2024-01-22 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded EVAX yet.
